The Feasibility of Pressurised Intraperitoneal Aerosolised Virotherapy (PIPAV) to Administer Oncolytic Adenoviruses

MLA

Sophia J. Tate, et al. “The Feasibility of Pressurised Intraperitoneal Aerosolised Virotherapy (PIPAV) to Administer Oncolytic Adenoviruses.” Pharmaceutics, vol. 13, no. 12, Nov. 2021, p. 2043. EBSCOhost, https://doi.org/10.3390/pharmaceutics13122043.

APA

Sophia J. Tate, Leen Van de Sande, Wim P. Ceelen, Jared Torkington, & Alan L. Parker. (2021). The Feasibility of Pressurised Intraperitoneal Aerosolised Virotherapy (PIPAV) to Administer Oncolytic Adenoviruses. Pharmaceutics, 13(12), 2043. https://doi.org/10.3390/pharmaceutics13122043

Chicago

Sophia J. Tate, Leen Van de Sande, Wim P. Ceelen, Jared Torkington, and Alan L. Parker. 2021. “The Feasibility of Pressurised Intraperitoneal Aerosolised Virotherapy (PIPAV) to Administer Oncolytic Adenoviruses.” Pharmaceutics 13 (12): 2043. doi:10.3390/pharmaceutics13122043.